News headlines about Thermo Fisher Scientific (NYSE:TMO) have trended somewhat positive on Saturday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Thermo Fisher Scientific earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 47.1301811550079 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have effected Accern’s analysis:
- Thermo Fisher To Buy Gatan For $925 Mln (nasdaq.com)
- Thermo Fisher to buy Roper Tech’s electron-microscope software unit (marketwatch.com)
- Thermo Fisher Scientific to acquire Gatan (seekingalpha.com)
- Thermo Fisher Scientific Signs Agreement to Acquire Gatan from Roper Technologies (finance.yahoo.com)
- Thermo Fisher to buy Roper Technologies unit for $925 mln (finance.yahoo.com)
Shares of Thermo Fisher Scientific opened at $207.14 on Friday, according to MarketBeat.com. The firm has a market cap of $82.72 billion, a P/E ratio of 20.77, a PEG ratio of 1.51 and a beta of 1.11. Thermo Fisher Scientific has a 1-year low of $170.07 and a 1-year high of $226.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.36.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 EPS for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.08. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The firm had revenue of $5.85 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same period in the previous year, the business posted $2.08 earnings per share. The company’s revenue for the quarter was up 22.8% compared to the same quarter last year. analysts predict that Thermo Fisher Scientific will post 10.9 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 16th. Shareholders of record on Friday, June 15th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 7.17%.
Several brokerages have recently issued reports on TMO. ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, June 20th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 price objective on the stock in a research note on Monday, April 30th. Finally, Morgan Stanley reduced their price objective on shares of Thermo Fisher Scientific from $228.00 to $216.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 11th. Two analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $224.38.
In other news, Director C Martin Harris sold 206 shares of the business’s stock in a transaction dated Friday, May 18th. The shares were sold at an average price of $214.43, for a total value of $44,172.58. Following the completion of the sale, the director now owns 5,106 shares of the company’s stock, valued at $1,094,879.58. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Wednesday, June 13th. The shares were sold at an average price of $217.71, for a total transaction of $10,885,500.00. Following the completion of the sale, the chief executive officer now directly owns 272,122 shares of the company’s stock, valued at approximately $59,243,680.62. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 97,706 shares of company stock valued at $21,125,673. Company insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.